We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
Turnover
40.17%
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter
Est. Return
+4.99%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$110B
AUM Growth
+$11.3B
(+11%)
Cap. Flow
+$10.7B
Cap. Flow
% of AUM
9.74%
Top 10 Holdings %
Top 10 Hldgs %
35.27%
Holding
3,643
New
809
Increased
972
Reduced
1,047
Closed
744
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
2
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
2.1
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3.35B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$2.85B |
| 3 |
Eli Lilly
LLY
|
+$999M |
| 4 |
Coca-Cola
KO
|
+$685M |
| 5 |
Broadcom
AVGO
|
+$616M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.38B |
| 2 |
Apple
AAPL
|
+$1.12B |
| 3 |
Netflix
NFLX
|
+$678M |
| 4 |
Boston Scientific
BSX
|
+$671M |
| 5 |
Cencora
COR
|
+$627M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.17% |
| 2 | Technology | 18.19% |
| 3 | Consumer Discretionary | 12.77% |
| 4 | Healthcare | 10.45% |
| 5 | Financials | 7.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
376
SLB Ltd
SLB
$73.5B
| $43.5M | 0.04% |
1,132,402
-281,567
| -20% | -$10.2M |
2025 Q2
2 quarters
|
|
377
CALL
iShares MSCI Brazil ETF
EWZ
$11.6B
| $43.2M | 0.04% |
1,361,100
+882,400
| +184% | +$27.9M |
2024 Q1
7 quarters
|
|
378
Nokia
NOK
$51.2B
| $42.9M | 0.04% |
6,623,145
-147,047
| -2% | -$911K |
2025 Q1
3 quarters
|
|
379
Lamb Weston
LW
$7.38B
| $42.8M | 0.04% |
1,022,143
+644,334
| +171% | +$37.9M |
2024 Q4
4 quarters
|
|
380
Viridian Therapeutics
VRDN
$2.16B
| $42.8M | 0.04% |
1,375,739
+506,551
| +58% | +$13.9M |
2025 Q1
3 quarters
|
|
381
STMicroelectronics
STM
$40.6B
| $42.7M | 0.04% |
+1,647,305
| New | +$42.3M |
2025 Q4
0 quarters
|
|
382
PUT
Advanced Micro Devices
AMD
$863B
| $42.5M | 0.04% |
198,400
-35,200
| -15% | -$7.91M |
2021 Q1
19 quarters
|
|
383
James Hardie Industries
JHX
$15B
| $42.5M | 0.04% |
2,045,950
+586,790
| +40% | +$11.8M |
2024 Q4
4 quarters
|
|
384
CrowdStrike
CRWD
$233B
| $42.3M | 0.04% |
361,308
-171,568
| -32% | -$21.8M |
2024 Q1
7 quarters
|
|
385
Jefferies Financial Group
JEF
$10.3B
| $42M | 0.04% |
678,550
-108,406
| -14% | -$6.21M |
2024 Q4
4 quarters
|
|
386
Brixmor Property Group
BRX
$8.49B
| $41.7M | 0.04% |
1,590,438
+648,579
| +69% | +$17.1M |
2025 Q2
2 quarters
|
|
387
Dianthus Therapeutics
DNTH
$4.03B
| $41.6M | 0.04% |
1,008,533
+435,595
| +76% | +$16.9M |
2025 Q3
1 quarter
|
|
388
CALL
iShares MSCI Emerging Markets ETF
EEM
$29.1B
| $41.4M | 0.04% |
757,100
-12,500
| -2% | -$680K |
2024 Q1
7 quarters
|
|
389
PUT
iShares China Large-Cap ETF
FXI
$3.89B
| $41.3M | 0.04% |
1,077,500
+983,600
| +1,047% | +$39M |
2022 Q2
14 quarters
|
|
390
HealthEquity
HQY
$7.61B
| $41.3M | 0.04% |
450,322
+157,140
| +54% | +$15M |
2025 Q2
2 quarters
|
|
391
Vale
VALE
$55.6B
| $41.2M | 0.04% |
3,165,210
-6,006,665
| -65% | -$73M |
2025 Q1
3 quarters
|
|
392
Markel Group
MKL
$22.9B
| $40.8M | 0.04% |
18,997
+9,416
| +98% | +$19.1M |
2024 Q2
6 quarters
|
|
393
PUT
Analog Devices
ADI
$192B
| $40.7M | 0.04% |
+150,000
| New | +$37.7M |
2025 Q4
0 quarters
|
|
394
TXNM Energy Inc
TXNM
$6.44B
| $40.6M | 0.04% |
689,412
+252,950
| +58% | +$14.6M |
2025 Q1
3 quarters
|
|
395
Fastenal
FAST
$58.5B
| $40.5M | 0.04% |
+1,008,013
| New | +$42.4M |
2025 Q4
0 quarters
|
|
396
Carrier Global
CARR
$45.3B
| $40.4M | 0.04% |
765,004
+701,115
| +1,097% | +$39M |
2024 Q3
5 quarters
|
|
397
Xylem
XYL
$24.3B
| $40.1M | 0.04% |
294,783
+293,261
| +19,268% | +$42.2M |
2023 Q1
11 quarters
|
|
398
DELISTED
Frontier Communications
FYBR
| $39.9M | 0.04% |
1,048,593
-814,379
| -44% | -$30.8M |
2024 Q1
7 quarters
|
|
399
Franco-Nevada
FNV
$47B
| $39.9M | 0.04% |
192,313
+186,654
| +3,298% | +$37.9M |
2025 Q2
2 quarters
|
|
400
Definium Therapeutics
DFTX
$4.31B
| $39.8M | 0.04% |
2,975,702
+593,722
| +25% | +$7.35M |
2024 Q1
7 quarters
|
|
Similar funds
Marshall Wace's Q4 2025 Portfolio in Review
As of Q4 2025, Marshall Wace held 3,643 positions worth $110B, up 11% from $98.6B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Marshall Wace deployed $10.7B of net new capital in Q4 2025, opening 809 new positions and adding to 972 existing holdings. Its largest new stake was Vanguard S&P 500 ETF: 4,580,704 shares worth $2.87B.
By sector, the portfolio is most concentrated in Miscellaneous at 30% of assets, up from 29% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Microsoft, an estimated $1.38B trimmed.
- Marshall Wace's largest Q4 2025 buy was Vanguard S&P 500 ETF: 4,580,704 shares worth $2.87B.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q4 2025, an estimated $3.35B increase.
- Marshall Wace's biggest Q4 2025 reduction was Microsoft, cutting an estimated $1.38B.
- Marshall Wace fully exited Ares Management in Q4 2025, selling an estimated $146M.
- Marshall Wace's ten largest holdings make up 35% of its $110B portfolio in Q4 2025.
- Marshall Wace opened 809 new positions and closed 744 in Q4 2025.
- Marshall Wace's portfolio value rose 11% quarter-over-quarter to $110B.
Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.